| Hazard Information | Back Directory | [Uses]
3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action[1][2][3]. | [in vivo]
3M-011 (1 mg/kg; intravenous injection; every other day with six doses; female scid/NOD mice) treatment shows antitumor effects in scid/NOD mice bearing B16-F10 cells[1].
Wild-type C57BL/6 mice are injected subcutaneously with different doses of 3M-011 (0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, or 10 mg/kg). 3M-011 induces a dose-dependent increase in serum concentrations of both TNF-α and IFN-α/β[1]. | Animal Model: | Female scid/NOD mice (8-12-week-old) injected with B16-F10 cells[1] | | Dosage: | 1 mg/kg | | Administration: | Intravenous injection; every other day with six doses | | Result: | Had antitumor effects in scid/NOD mice bearing B16-F10 cells.
|
| [IC 50]
TLR7; TLR8; H3N2 influenza viral | [References]
[1] Dumitru CD, et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother. 2009 Apr;58(4):575-87. DOI:10.1007/s00262-008-0581-7
[2] Hammerbeck DM, et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 2007 Jan;73(1):1-11. DOI:10.1016/j.antiviral.2006.07.011
[3] Sch?lch S, et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget. 2015 Mar 10;6(7):4663-76. DOI:10.18632/oncotarget.3081 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
www.chemicalbook.com/showsupplierproductslist927327/0_en.htm |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|